Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Inclusion Criteria: * Age \> 16 years * Biopsy-proven diagnosis of classical Hodgkin Lymphoma (regardless of HRS cell CD20 expression) per the World Health Organization classification criteria24; lymphocyte predominant histology is excluded * Untreated relapse of classical Hodgkin Lymphoma (with the exception of steroids) as follows:HL that relapsed \> 3 months after completion of first-line chemotherapy or combined modality therapy, and has not yet been treated with salvage chemotherapy, Stage I-II HL that relapsed \> 3 months after first-line chemotherapy, then relapsed after radiation therapy delivered with curative intent, and has not yet been treated with salvage chemotherapy * Radiographically measurable disease (\> 1 focus of lymphoma measuring \> 1.5 cm) * Baseline laboratories: ANC \> 1000/uL and platelets \> 75,000/uL, unless due to bone marrow involvement by lymphoma, Serum creatinine \< 2.0 mg/dL, Total bilirubin \< 2.0 mg/dL (excluding Gilbert's syndrome), unless due to lymphoma * ECOG performance status 0, 1 or 2. Exclusion Criteria: * Active concurrent malignancy with the exception of superficial non-melanoma skin cancer and cervical carcinoma in situ. * Primary induction failure, defined as failure to achieve CR with first-line chemotherapy or chemoradiation, disease progression during first-line chemotherapy or chemoradiation, or progression or biopsy-proven disease persistence within 8 weeks of first-line therapy completion * Prior brentuximab vedotin or rituximab for lymphoma * Grade \> 2 peripheral neuropathy * HIV infection, active hepatitis B infection, or active hepatitis C infection